Skip to main content

Table 2 Tumour uptake of 89Zr-RG7356 and RG7356 at 96 h p.i.

From: Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

Patient

Dose cohort (mg)

Visual assessment

Localisation

SUVpeak

AUC (mg h/mL)

Tumour-to-blood AUC ratio

1

1

2

100

3

100

*

4

100

5

200

6

200

7

450

+

Brain L

1.8

0.35

0.09

Lung R

8.4

2.06

0.55

8

450

+

Skull L

3.3

1.41

0.43

Upper neck L

3.5

1.62

0.49

Lower neck L

2.8

1.43

0.43

Supraclavicular R

3.1

1.67

0.50

Mediastinal

4.8

2.37

0.72

Lung L

2.2

1.29

0.39

Lung R1

2.1

1.06

0.32

Lung R2

4.3

1.75

0.53

9

450

+

Lung L

1.8

0.89

0.32

Lung R

2.2

0.99

0.36

Rectum

5.6

1.75

0.64

10

450

+

Lung L

4.6

1.47

0.56

Lung R

3.9

1.41

0.53

11

450

+

Mastoid L

4.5

1.81

0.42

12

675

+

Sigmoid L

4.9

2.55

0.59

13

675

+

Pelvic R

6.5

3.83

0.73

Sacrum

8.1

3.29

0.63

  1. no visible tumour uptake
  2. *Diffuse uptake in the lung